Showing posts with label Parkinson disease. Show all posts
Showing posts with label Parkinson disease. Show all posts

Wednesday, 7 September 2011

Neurobiology of Tourettes Syndrome

Tourette Sydrome is a neuropsychiatric, childhood-onset disorder characterized my motor tics in addition to vocal (phonic) tics.  Original estimates of the prevalence of this condition was that it was very rare.  However, it appears that many individuals with the condition has a relatively mild form of the disorder.  Including these individuals produces a prevalence rate of between .1% and 1% of the population.

Common motor tics presenting on average around ages 5 to 7 years of age include eye blinking, facial twitching, sniffing and shoulder shrugging.  The most common motor tic is throat clearing.  Outbursts of shouting profanities is commonly felt to be common in Tourette Syndrome but actually occurs in only 10% of cases.

Ryan Felling and Harvey Singer recently published an excellent overview of the neurobiology of Tourette Sydnrome in The Journal Neuroscience.  This review includes an introduction to the syndrome before examining brain circuits, animal models, structural and functional brain imaging findings.  

The authors note that brain structural and functional abnormalities in Tourette Syndrome appear diffusely located but do involve the brain stuctures related to motor control including the basal ganglia (See Brain Tutor.  There are several known neuropsychiatric conditions of the basal ganglia that produce motor abnormalities.  

Parkinson's disease is an abnormality of the basal ganglia's substantia nigra producing slowed motor movements with muscle rigidity.  Huntington's disease produces atrophy of the basal ganglia region known as the head of the caudate and is characterized by jerky, uncontrolled movements known as chorea.

The structure and functional brain imaging studies to date in Tourettes Sydrome have demonstrated a variety of effects in the basal ganglia including:
  • reduced caudate volume (smaller caudate size linked to greater tic severity)
  • enlarged putamen
  • activity in putament and caudate (and cortex) correlate with tic activity
  • decreased activity in the putamen and caudate with attempts to suppress tic
The review notes that Tourette Syndrome appears to be due to "pathololgic involvement of the cortico-striatal (putamen/caudate)-thalamo-cortico" brain circuits with dysfunction of the neurotransmitter dopamine a key contributor to disorder. 

The authors note that no effective treatment exists for Tourette Syndrome.  Interventions focus on behavioral and drug treatment with an emphasis on treating the common co-occuring disorders: OCD and ADHD.  Thankfully, symptoms often reduce in frequency and severity with age.  

The authors conclude significant additional research is needed using larger samples with better description of specific tic patterns, control for comorbid ADHD and OCD and focus on whether brain changes found in Tourette Sydrome are primary or may result from compensatory mechanism in response to tic motor behaviors. 

Interested readers can learn more about this disorder from a excellent series of discussion by patients with Tourettes Syndrome from the New York Times Patient Voices Multimedia project here

Screen Shot of Basal Ganglia Structures from Brain Tutor iPad app.

Felling RJ, & Singer HS (2011). Neurobiology of tourette syndrome: current status and need for further investigation. The Journal of neuroscience : the official journal of the Society for Neuroscience, 31 (35), 12387-95 PMID: 21880899

Wednesday, 16 February 2011

Brain Stimulation for Parkinson Disease: Expert Opinion


Parkinson disease is a chronic progressive disease with significant impairment and distress.  A host of pharmacological options are available. Unfortunately, drug treatment often is only partially successful in reducing symptoms and can produce problematic adverse events.  Deep brain stimulation (DBS) has emerged as a potential therapeutic option for those with severe Parkinson disease.  DBS involves a neurosurgical procedure that places an electrode or electrodes into the brain with a device to modulate an electric current.  The brain subthalamic nuclei has become the most common site for DBS electrode placement.

Many questions remain unanswered in DBS therapy for Parkinson disease.  A recent consensus conference assembled 49 experts in the use and care of patients receiving DBS therapy.  They have published their recommendations in a recent manuscript published in Archives of Neurology.  I will summarize some of their recommendations:

Surgical Selection:  Expert selection of candidates for DBS is viewed as the most important variable in getting a good DBS outcome.  Best candidates for DBS include those with the following features:
  • Excellent response to the drug levodopa
  • Younger age
  • No or few axial motor symptoms that do not respond to levodopa
  • Limited cognitive impairment
  • Limited or well-controlled psychiatric disease
Surgical Complications: Surgical complications are not common but are not trivial and need to be taken into account when considering DBS surgery.  Complications can include intracranial hemorrhage (bleeding), stroke, infection, erosion of DBS leads, and death.  Advanced age and medical comorbidities appear to increase the risks for surgical complications but should not be absolute contraindications.  Surgical team experience is important and patients and their families should select centers with extensive experience with the procedure.  There is a need for a standardized system of reporting DBS complications to allow for comparison across treatment sites.

Parkinson Disease Outcome: If a patient has improvement in gait and speech with levodopa, they are more likely to have improvement in these domains with DBS.  Initial improvement in gait and speech with DBS may later fade as the disease progresses.  Some patients experience increase in depression after DBS and this may be related to the site of the electrodes.  Patients need to have depression, anxiety, apathy, psychosis and impulsivity levels assessed before surgery as these parameters may complicate outcome.  Improvement in some aspects of Parkinson disease has been demonstrated for up to 5 years.  Nevertheless, progression of disease commonly occurs in good DBS repsonders and DBS does not prevent the late stages of Parkinson disease including freezing of gait, postural instability and cognitive decline.

This expert consensus guideline will aid clinicians, patients and family members in considering DBS as a therapeutic option.  A patient resource for those with Parkinson disease considering DBS can be found here (DBS-STN.org-an affiliate of the Parkinson Alliance).

Figure of coronal section of brain showing subthalamic nuclei (STN in yellow)--common electrode placement site in DBS for Parkinson disease.  Figure courtesy of Creative Commons from Wikipedia, author Andrew Gillies.

Bronstein, J., Tagliati, M., Alterman, R., Lozano, A., Volkmann, J., Stefani, A., Horak, F., Okun, M., Foote, K., Krack, P., Pahwa, R., Henderson, J., Hariz, M., Bakay, R., Rezai, A., Marks, W., Moro, E., Vitek, J., Weaver, F., Gross, R., & DeLong, M. (2010). Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues Archives of Neurology, 68 (2), 165-165 DOI: 10.1001/archneurol.2010.260